Estrogen use after menopause has a complex medical history. It was once widely prescribed but later became controversial due to studies linking it to increased risks of dementia, cancer, and cardiovascular issues.
Recent research from Stanford Medicine suggests that a specific form of hormone therapy may tell a different story. Women who used only estrogen showed fewer physical indicators of Alzheimer’s disease in their brains after death and were less often diagnosed with dementia during their lives.
It’s important to distinguish between estrogen-only therapy and other hormone treatments. Typically, estrogen alone is prescribed to women who’ve had a hysterectomy, meaning they no longer have a uterus.
Women with uteruses usually receive additional hormones, such as progesterone, along with estrogen. This combination is to protect the uterine lining and reduce cancer risk.
The new findings primarily concern women who used estrogen-only therapy. Not all hormone treatments showed benefits, making this distinction significant.
The investigation into hormones and Alzheimer’s is especially relevant because women make up roughly two-thirds of Alzheimer’s cases, and estrogen influences many parts of the body, including the brain.
Alzheimer’s progressively damages nerve cells involved in memory, reasoning, and daily functioning. It’s characterized by abnormal buildup of amyloid plaques outside the cells and tau protein tangles inside them.
While diagnosing dementia clinically provides helpful information, it’s not perfect because multiple factors can cause memory problems. Conditions like strokes, other dementias, medications, depression, and temporary illnesses can all impact cognition, especially in older adults.
Because of these complexities, Stanford researchers decided to analyze the brains directly. Led by senior author Hadi Hosseini, they examined autopsy data to assess physical signs associated with Alzheimer’s disease.
The team reviewed data from two large databases including 21,462 individuals. They identified women whose brains had been examined after death and compared their history of menopausal hormone therapy with the amount of Alzheimer’s-related damage observed during autopsy.
In particular, they focused on 258 women who had used estrogen-only therapy and about 2,701 women who did not use any menopausal hormone treatment. They evaluated amyloid plaques, tau tangles, and the density of amyloid deposits.
The results favored estrogen-only users, whose brains showed significantly fewer Alzheimer’s-associated changes. Statistical analysis indicated approximately a 35% reduction in the likelihood of Alzheimer’s pathology among them.
Beyond autopsy findings, the researchers examined data collected during the women’s lives, including dementia diagnoses, memory assessments, and ability to perform daily activities.
Women who used estrogen alone had a 39% lower chance of having been diagnosed with dementia. They also performed better on memory tests and could manage everyday tasks more effectively.
These findings persisted even after adjusting for several known risk factors like age, hypertension, education, race, and the presence of the APOE4 gene, which strongly influences Alzheimer’s risk.
This is especially notable because previous studies on hormone therapy produced mixed results. Some observational research suggested estrogen might protect the brain, but later clinical trials cast doubt on these claims.
The Women’s Health Initiative Memory Study (published in 2003) was influential, finding that women taking estrogen with progestin had an increased risk of dementia, especially when starting therapy later in life.
These results significantly impacted public perceptions of menopausal hormone therapy, leading to decreased use and heightened caution from healthcare providers over the years.
However, scientists now question whether findings from one group of women and a specific hormone regimen apply broadly. Timing of hormone initiation—close to menopause or much later—may affect outcomes. Additionally, estrogen alone might behave differently than estrogen combined with progestin.
The Stanford study couldn’t determine the effects of combined therapy due to limited data on women using estrogen plus progestin and available brain tissue samples. It also excluded topical estrogen treatments, so results don’t necessarily apply to patches or gels.
The women studied were generally older, averaging around 70, and many had undergone hysterectomies. The researchers noted current clinical guidelines often favor starting hormone therapy during or shortly after menopause when symptoms begin.
The study was published on August 12, 2026, in the journal Neurology, led by Stanford Medicine researchers including Hadi Hosseini and Jennifer Bruno. It’s the first to analyze a large number of postmortem brains directly for Alzheimer’s pathology in the context of menopausal hormone use.
This approach is valuable since autopsy findings are less influenced by subjective memory reports. Correlating physical brain changes with diagnostic and testing information strengthens the overall conclusions.
Nonetheless, the study can’t prove causality. It didn’t randomly assign women to hormone use, so unmeasured differences might partly explain the observed association.
Therefore, these results shouldn’t be taken as a reason to start hormone therapy solely for brain health. Hormone treatments can carry risks depending on individual health and age.
The key takeaway is that estrogen-only therapy doesn’t necessarily fit with the old idea that menopausal hormones increase dementia risk. Instead, it may be linked to a meaningful decrease in Alzheimer’s signs in some women.
Future research should explore different formulations, doses, onset timings, and durations to clarify these effects. If clinical trials confirm a protective benefit, physicians could consider hormone therapy not just for menopausal symptoms but also for supporting long-term brain health.
Source: Stanford Medicine
